Notwithstanding encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from PBMs. The companies are typically creating limitations to coverage, like high cost criteria and approval processes t